French healthcare company Sanofi has agreed to buy Austrian group Origimm Biotechnology in a move that Sanofi said would boost its vaccines business.
"The acquisition of Origimm further broadens our vaccines research and development pipeline with a first vaccine candidate against acne, a high medical need for millions of teenagers and adults," said Thomas Triomphe, executive vice president and global head of Sanofi Pasteur, on Wednesday.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.